Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott Fung, Marı́a Buti, Sang Hoon Ahn et al.|Alimentary Pharmacology & Therapeutics|2023Cited by 14
Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B PatientsJinlin Hou, Jidong Jia, Qin Ning et al.|Journal of Clinical and Translational Hepatology|2024Cited by 7